Interaction of the anxiogenic agent, RS-30199, with 5-HT(1A) receptors: Modulation of sexual activity in the male rat

Neuropharmacology

Volumn 37, Issue 6, 1998, Pages 769-780

  Spedding, M ^a   Newman Tancredi, A ^a   Millan, M J ^a   Dacquet, C ^a   Michel, A N ^a   Jacoby, E ^a   Vickery, B ^b   Tallentire, D ^b  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

5 HT(1A) receptor; Anxiety; Buspirone; Delequamine; Drug design; Receptor ligand interaction; RS 30199; Sexual behavior

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 CHLORO 2 [4 (8 AZASPIRO[4,5]DECANE 7,9 DIONE) BUT 1 YL] 1,2,3,4,8,9,10,10A OCTAHYDRONAPHTH[1,8 CD] 3 AZEPINE; 5 CHLORO 2 METHYL 1,2,3,4,8,9,10,10A OCTAHYDRONAPHTH[1,8 CD]AZEPINE; BUSPIRONE; DELEQUAMINE; ESTRADIOL BENZOATE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); PROGESTERONE; RS 30199 193; RS 30199 197; RS 30199 198; RS 64459 193; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENANTIOMER; FEMALE; LIGAND BINDING; MALE; MOLECULAR MODEL; NEUROMODULATION; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC TRANSMISSION; SEXUAL BEHAVIOR; SUBCUTANEOUS DRUG ADMINISTRATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTI-ANXIETY AGENTS; AZEPINES; CHO CELLS; CRICETINAE; FEMALE; HUMANS; MALE; MODELS, CHEMICAL; NAPHTHALENES; NAPHTHYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; SEXUAL BEHAVIOR, ANIMAL;

EID: 0031811333     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00065-3     Document Type: Article

References (79)

1. Ahlenius S., Larsson K., Svensson L., Hjorth S., Carlsson A., Lindberg P., Wikstrom H., Sanchez D., Arvidsson L.E., Hacksell U., Nilsson J.L. Effects of a new type of 5-HT receptor agonist on male rat sexual behaviour. Pharmacol. Biochem. Behav. 15:1981;785-792.
2. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology. 1991;281-315 Wiley, New York.
3. 2 receptor antagonistic properties, on male rat sexual behavior. Eur. J. Pharmacol. 255:1994;131-137.
4. 2 adrenoceptor antagonist on sleep and nocturnal penile tumescence in normal male volunteers and men with erectile dysfunction. Psychosom. Med. 57:1995;345-356.
5. 1A receptor ligands using a three dimensional model. Sanz F., Giraldo J., Manout F. QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications. 1995;541-544 Prons.
6. Bitran D., Hull E.M. Pharmacological analysis of male sexual behaviour. Neurosci. Behav. Rev. 11:1987;365-387.
7. Brancheck T. Site-directed mutagenesis of serotonin receptors. Med. Chem. Res. 3:1993;287-296.
8. 1Dβ receptors. Eur. J. Med. Chem. 32:1997;59-69.
9. 1A site. Br. J. Pharmacol. 98:1989;681P.
10. 2-adrenoceptor antagonist. Br. J. Pharmacol. 108:1992;516-525.
11. Cascieri M.A., Fong T.M., Strader C.D. Identification of critical functional groups within binding pockets of G-protein-coupled receptors. Drugs Future. 21:1996;521-527.
12. 1A serotonin receptor. Mol. Pharmacol. 43:1993;516-520.
13. 1A receptors. Am. Soc. Neurosci. 23:1997;5914.
14. Charney D.S., Heninger G.R., Redmond D.E. Jr. Yohimbine-induced anxiety and increased noradrenergic function in humans: effect of diazepam and clonidine. Life Sci. 33:1983;19-29.
15. Charney D.S., Heninger G.R., Breier A. Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch. Gen. Psychiatry. 41:1984;751-763.
16. Charney D.S., Woods S.W., Goodman W.K., Heninger G.R. Neurobiological mechanisms of panic anxiety: biochemical and behavioral corrolates of yohimbine-induced panic attacks. Am. J. Psychiatry. 144:1987;1030-1036.
17. Charney D.S., Woods S.W., Krystal J.H., Nagy L.M., Heninger G.R. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr. Scand. 86:1992;273-282.
18. Cheng C.H.K., Costall B., Ge J., Naylor R.J. The profiles of interaction of yohimbine with anxiolytic and putative anxiolytic agents to modify 5-HT release in the frontal cortex of freely-moving rats. Br. J. Pharmacol. 110:1993;1079-1084.
19. Clark T.J., Smith E.R., Davidson J.M. Testosterone is not required for the enhancement of sexual motivation by yohimbine. Physiol. Behav. 35:1984;517-521.
20. Clark T.J., Smith E.R., Davidson J.M. Enhancement of sexual motivation in male rats by yohimbine. Science. 225:1985;847-849.
21. 2-adrenoceptor antagonist. J. Med. Chem. 32:1989;2034-2036.
22. 1A agonist and potential anxiolytic agent. Drug Dev. Res. 26:1992;21-48.
23. Deakin J.F.W. Three distinct roles of 5-HT in anxiety, panic and depression. Montgomery S.A., Corn T.H. Psychopharmacology of Depression. 1994;87-101 Oxford University Press, London.
24. Donnelly D., Findlay J.B.C., Blundell T.L. The evolution and structure of aminergic G protein-coupled receptors. Recept. Channel. 2:1994;61-78.
25. 1A receptor. J. Biol. Chem. 264:1989;14848-14852.
26. i protein. Cell. Signal. 3:1991;547-557.
27. 1A agonist. J. Pharmacol. Exp. Ther. 267:1993;58-71.
28. 1A receptors and antidepressant drug action. Montgomery S.A., Corn T.H. Psychopharmacology of Depression. 1994;66-86 Oxford University Press, London.
29. Gaillard P., Corrupt P-A., Testa B., Schambel P. Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridinylindoles to the 5-HT receptor: contribution of the molecular lipohilicity potential to three-dimensional quantitative structure-activity relationship models. J. Med. Chem. 39:1996;126-134.
30. 1A serotonin binding sites? J. Med. Chem. 32:1989;1921-1926.
31. 2-adrenoceptor. Pharmacol. Rev. 35:1983;143-180.
32. 1A receptor interactions. J. Med. Chem. 39:1996;3491-3502.
33. Henderson R., Baldwin J., Ceska T., Zemlin F., Beckmann E., Downing K. Model for the structure of bacteriorhodopsin based on high-resolution electron cryomicroscopy. J. Mol. Biol. 213:1990;899-929.
34. 3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding. Mol. Pharmacol. 33:1988;303-309.
35. 2 dopamine receptor. Endocr. J. 2:1994;7-23.
36. 1 antagonists. J. Recept. Signal Transduct. Res. 17:1997;855-873.
37. Jacobsen F.M. Fluoxetine-induced sexual dysfunction and an open trial of yohimbinem. J. Clin. Psychiatr. 53:1992;119-122.
38. 1A receptor agonist. Mol. Neuropharmacol. 2:1992;283-288.
39. Kristiansen K., Dahl S., Edvardsen O. A database of mutants and effects of site-directed mutagenesis experiments on G protein-coupled receptors. Proteins Struct. Funct. Genet. 26:1996;81-94.
40. 1A receptor: agonist and antagonist binding sites. Drug Des. Discov. 11:1994;231-249.
41. 1-arylpiperazines. J. Med. Chem. 40:1997;300-312.
42. Lewel X.Q. A model of the adrenergic β-2 receptor and binding sites for agonists and antagonists. Drug Des. Discov. 9:1992;29-48.
43. 2 receptor binding sites. Mol. Pharmacol. 21:1982;301-314.
44. 2-adrenoceptors: implications for receptor classification. Br. J. Pharmacol. 106:1992;1011-1018.
45. MacKinnon A.C., Kilpatrick A.T., Kenny B.A., Brown C.M., Kilpatrick A.T., Martin A.B., Williams A., Clague R.U., Spedding M. Modulation of central noradrenergic function by RS-15385-197. Br. J. Pharmacol. 108:1992;523-526.
46. Mason B.J., Kocsis J.H., Leon A.C., Thompson S., Frances A.J., Morgan R.O., Parides M.K. Measurement of severity and treatment response in dysthymia. Psychiatr. Ann. 23:1993;625-631.
47. 1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites, respectively. Eur. J. Pharmacol. 230:1993;99-102.
48. 1A receptors. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. J. Pharmacol. Exp. Ther. 282:1996;148-161.
49. Morales A., Surridge D.H.C., Marshall P.G., Fenemore J. Non-hormonal pharmacological treatment of organic impotence. J. Urol. 128:1982;45-47.
50. Moulton B., Morinan A. The effect of RS-30199 on anxiety and hippocampal monoamine oxidase activity in the rat. Br. J. Pharmacol. 101:1990;516P.
51. 0-like G protein. J. Biol. Chem. 269:1994;12954-12962.
52. 2 adrenoceptor antagonist on erectile function in the human male. 1. The erectile response to erotic stimuli in volunteers. Psychopharmacology. 115:1994;463-470.
53. 2 adrenoceptor antagonist on erectile function in the human male. 2. The erectile response to erotic stimuli in volunteers. Psychopharmacology. 115:1994;470-473.
54. 1A 5-hydroxytryptamine receptors in Chinese hamster ovary cells. Biochem. J. 285:1992;933-938.
55. 1A receptors. Neuropharmacology. 35:1996;119-121.
56. Oliveira L., Paiva A.C.M., Vriend G. A common motif in G-protein-coupled seven transmembrane helix receptors. J. Comput. Aided Mol. Design. 7:1993;649-658.
57. Pazos A., Hoyer D., Palacios J.M. The binding of serotoninergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur. J. Pharmacol. 106:1984;546-593.
58. sα. Biochemistry. 32:1993;11064-11073.
59. Redfern W.S., Clague R.U., Spedding M. Anxiogenic-like properties of RS-30199 in the rat. Br. J. Pharmacol. 98:1989;682P.
60. Redfern W.S., MacKinnon A.C., Brown C.M., Kilpatrick A.T., Martin A.B., Williams A., Clague R.U., Spedding M. Modulation of central noradrenergic function by RS-15385-197. Br. J. Pharmacol. 108:1992;523-526.
61. 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat. Br. J. Pharmacol. 116:1995;2081-2089.
62. Reid K., Surridge D.H.C., Morales A., Condra M., Harris C., Owen J., Fenmore J. Double blind trial of yohimbine in the treatment of psychogenic impotence. Lancet. ii:1987;421-423.
63. Röper D., Krüger P., Grötzinger J., Wollmer A., Straßbruger W. Models of G-protein coupled receptors revised for family-wide compliance with experimental data. A new sequence accommodation suggested for helix G. Recept. Channel. 3:1995;97-106.
64. 1A receptors in the anxiolytic action of S 14671 in the pigeon conflict test. Pharmacol. Biochem. Behav. 51:1995;211-215.
65. Schwartz T.W., Rosenkilde M.M. Is there a lock for all agonist keys in 7TM receptors? Trends Pharmacol. Sci. 17:1996;213-215.
66. Schwartz T.W., Rosenkilde M.M. Schwartz and Rosenkilde replay dogmas versus Data in 7TM locks for keys. Trends Pharmacol. Sci. 17:1996;347.
67. 2A receptor. J. Biol. Chem. 270:1995;16683-16688.
68. 7 serotonin receptor subtype. J. Biol. Chem. 268:1996;18200-18204.
69. 1A receptors: anomalous effects with RS-30199-193. Br. J. Pharmacol. 104:1991;519-525.
70. 2-Adrenoceptor antagonists and male sexual behaviour: I. Mating Behaviour. Physiol. Behav. 41:1987;7-14.
71. Södersten P., Dammassa D.A., Smith E.R. Sexual behaviour in developing male rats. Horm. Behav. 8:1987;320-334.
72. Spedding M., Dacquet C. Transduction is a major factor influencing receptor characterisation. Ann. New York Acad. Sci. 812:1996;29-40.
73. Strange P. 7TM Receptors-Locks and Keys. Trends Pharmacol. Sci. 17:1996;346-346.
74. 1A receptor. J. Pharm. Pharmacol. 49:1997;689-705.
75. 2-adrenoceptor antagonist, delequamine (RS-15385-197). Br. J. Pharmacol. 118:1996;63-72.
76. 1 receptor and of catecholamine systems in the behavioral response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur. J. Pharmacol. 106:1984;271-275.
77. Van Rhee A.M., Jacobson K.A. Molecular architecture of G-protein-coupled receptors. Drug Dev. Res. 37:1996;1-38.
78. Winter J.C., Rabin R.A. Yohimbine as a serotoninergic agent: evidence from receptor binding and drug discrimination. J. Pharmacol. Exp. Ther. 263:1992;682-689.
79. 1A binding sites in the rat CNS and the guinea-pig ileum. Pharm. Weekblad. Sci. Ed. 10:1988;301.